Q3 Earnings Forecast for CBIO Issued By HC Wainwright

Crescent Biopharma, Inc. (NASDAQ:CBIO) – Equities researchers at HC Wainwright issued their Q3 2025 earnings per share estimates for Crescent Biopharma in a research note issued on Monday, August 11th. HC Wainwright analyst M. Kapoor forecasts that the biopharmaceutical company will post earnings per share of ($1.29) for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Crescent Biopharma’s current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Crescent Biopharma’s Q4 2025 earnings at ($1.31) EPS, FY2025 earnings at ($8.43) EPS, Q1 2026 earnings at ($1.33) EPS, Q2 2026 earnings at ($1.36) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.42) EPS and FY2026 earnings at ($5.49) EPS.

Other equities research analysts have also recently issued research reports about the company. Wedbush initiated coverage on Crescent Biopharma in a research note on Monday, July 14th. They set an “outperform” rating and a $27.00 target price for the company. TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a research note on Friday, June 20th. Wall Street Zen cut Crescent Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 2nd. Lifesci Capital raised Crescent Biopharma to a “strong-buy” rating and set a $22.00 target price for the company in a research note on Wednesday, June 18th. Finally, Stifel Nicolaus initiated coverage on Crescent Biopharma in a research note on Wednesday, June 25th. They set a “buy” rating and a $28.00 target price for the company. One analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Crescent Biopharma has a consensus rating of “Buy” and an average target price of $25.50.

Crescent Biopharma Stock Performance

NASDAQ:CBIO opened at $13.90 on Wednesday. The firm has a 50 day moving average of $13.88. The firm has a market capitalization of $271.75 million, a PE ratio of -0.40 and a beta of 1.51. Crescent Biopharma has a one year low of $10.83 and a one year high of $63.00.

Crescent Biopharma (NASDAQ:CBIO) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($4.93) EPS for the quarter, missing the consensus estimate of ($2.69) by ($2.24).

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Crescent Biopharma stock. Jefferies Financial Group Inc. purchased a new position in shares of Crescent Biopharma, Inc. (NASDAQ:CBIO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 27,096 shares of the biopharmaceutical company’s stock, valued at approximately $437,000. Jefferies Financial Group Inc. owned 0.14% of Crescent Biopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 75.19% of the company’s stock.

About Crescent Biopharma

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.